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The MYC oncogene codes for a transcription factor that is overexpressed in many human cancers. Here we show that MYC regulates the expression of two immune checkpoint proteins on the tumor cell surface: the innate immune regulator CD47 (cluster of differentiation 47) and the adaptive immune checkpoint PD-L1 (programmed death-ligand 1). Suppression of MYC in mouse tumors and human tumor cells caused a reduction in the levels of CD47 and PD-L1 messenger RNA and protein. MYC was found to bind directly to the promoters of the Cd47 and Pd-l1 genes. MYC inactivation in mouse tumors down-regulated CD47 and PD-L1 expression and enhanced the antitumor immune response. In contrast, when MYC was inactivated in tumors with enforced expression of CD47 or PD-L1, the immune response was suppressed, and tumors continued to grow. Thus, MYC appears to initiate and maintain tumorigenesis, in part, through the modulation of immune regulatory molecules.
T he transcription factor MYC regulates the expression of a multitude of gene products involved in cell proliferation, growth, selfrenewal, differentiation, and apoptosis (1) (2) (3) (4) . The MYC gene is genetically activated and overexpressed in many human cancers (1) (2) (3) (4) , and this overexpression has been causally linked to tumorigenesis (5, 6) . Studies involving inducible transgenic mouse models have shown that growth of Myc-induced tumors is dependent on continuous expression of MYC (1) (2) (3) (4) (7) (8) (9) (10) . For example, in the tetracycline-off mouse model (where Myc expression can be turned off by the addition of tetracycline or doxycycline), tumors grow only when Myc is "on." When Myc is turned "off," tumors regress.
In mouse models, MYC inactivation results in tumor regression through the induction of proliferative arrest and apoptosis (1-3, 7, 8, 10-12) . We have demonstrated that complete tumor clearance that occurs after the inactivation of oncogenes, including Myc, requires the recruitment of CD4 + T cells and the secretion of thrombospondin-1 (13, 14) . Hence, a host-dependent immune response is required for sustained tumor regression. However, the mechanism by which oncogene inactivation elicits this immune response is unknown.
The host immune system generally serves as a barrier against tumor formation (15) . Activation of the immune response can contribute to tumor regression (13, 16, 17) through both adaptive and innate immune effectors (18) (19) (20) . Programmed death-ligand 1 (or PD-L1, also known as CD274 and B7-H1) sends a critical "don't find me" signal to the adaptive immune system (21-23), whereas (26) (27) (28) (29) .
To explore whether and how MYC regulates the antitumor response, we examined its effect on the expression of CD47 and PD-L1 in the Tetoff transgenic mouse model of MYC-induced T cell acute lymphoblastic leukemia (MYC T-ALL). When MYC was turned on, both CD47 and PD-L1 were expressed. However, in vitro or in vivo Myc inactivation resulted in a rapid down-regulation of CD47 and PD-L1-both at the mRNA level, as detected by quantitative real-time polymerase chain reaction (qPCR), and at the protein level, as detected by flow cytometry (Fig. 1, A and B) and immunofluorescence ( fig. S1B) . Expression of other immune-related surface receptors was not affected by MYC inactivation (Fig. 1A) . Consistent with these observations, suppression of MYC expression in the human T-ALL cell lines CCRF-CEM and Jurkat, either by treatment with a MYCtargeting short hairpin RNA (shRNA) ( fig. S2A ) or with the BET (bromodomain and extraterminal) inhibitor JQ1 (30) , reduced the expression of CD47 and PD-L1 (Fig. 1C) . Treatment of MYC T-ALL cells with the chemotherapeutic drugs prednisone, cytoxan, cisplatin, or vincristine, resulted in tumor cell death. However, CD47 and PD-L1 were either unaffected or showed increased expression (fig. S3A), and there was no effect on the expression of CD3, CD8, CD25, or CD69 ( fig. S3 , B to E).
We next investigated the effect of MYC inactivation on CD47 and PD-L1 in mouse and human solid tumors. In a Tet-off transgenic mouse model of hepatocellular carcinoma (HCC) (3), inhibition of MYC expression resulted in decreased levels of CD47 and PD-L1 protein ( fig. S4, A and B) and mRNA (fig. S4B) ; expression of the two proteins was not affected by cisplatin treatment (fig.  S4A ). In the human HCC cell line HEPG2, shRNA knockdown of MYC caused a reduction in the levels of both CD47 and PD-L1 mRNA ( fig. S4C ). We also investigated the relationship between MYC expression and CD47 and PD-L1 expression in the human melanoma cell line SKMEL28 ( Fig. 2A ) and the human non-small cell lung cancer (NSCLC) cell line H1299 (Fig. 2B ), as these cells represent tumor types that are often treated with immune checkpoint inhibitors in the clinic (31) . We found that MYC shRNA knockdown and MYC functional suppression by JQ1 reduced the expression of CD47 and PD-L1 mRNA and protein as measured by qPCR and flow cytometry, respectively.
In additional experiments, we found that MYC shRNA knockdown ( fig. S2B ) or JQ1 treatment of four independent primary human T-ALL samples reduced both CD47 and PD-L1 cell surface expression ( fig. S5 ). Cisplatin treatment increased CD47 and PD-L1 expression, whereas CD8 expression was unaffected by the treatments ( fig. S5 ). Last, we examined publicly available gene expression data derived from human primary tumors. Notably, in human HCC, renal cell carcinoma, and colorectal carcinoma, MYC expression significantly correlated with the expression of both CD47 and PD-L1 ( fig. S6 ). Thus, MYC regulates CD47 and PD-L1 expression in multiple human tumor types.
MYC can act as a general transcriptional amplifier (that is, it can generally increase expression of many genes rather than specific target genes), but dosage-dependent specific effects have been reported (32) (33) (34) (35) (36) . We analyzed chromatin immunoprecipitation sequencing (ChIP-seq) data from mouse MYC T-ALL cells (34) and the human B cell line P493-6 (37, 38) and found high levels of MYC bound to the promoter regions of the genes coding for CD47 and PD-L1 ( binding to the promoters of other cell surface immune molecules such as CD8a and CD25. Oncogenic levels of MYC bound the CD47 and PD-L1 gene promoters in human osteosarcoma U2OS cells, whereas low levels of MYC did not ( fig. S9) . In a nuclear run-on assay with P493-6 cells, MYC induced expression of the CD47 gene, along with other well-known target genes such as PDK1, CHEK1, CDK2, LDHA, and ODC1 ( fig. S10, A and B) . PD-L1 expression was too low to measure changes in this experiment. Thus, we conclude that MYC binds to the promoters and directly regulates the expression of the CD47 and PD-L1 genes. An alternative but not mutually exclusive possibility is that MYC suppression acutely affects CD47 and PD-L1 surface protein expression by reducing the half-lives of the two proteins. However, we did not observe the increased turnover of CD47 or PD-L1 proteins compared with other immune surface proteins in mouse MYC T-ALL cells when we inhibited protein synthesis by cycloheximide treatment (fig. S11 ).
We have shown previously that MYC inactivation in mouse tumor models results in recruitment of immune cells to the tumors (13) . To investigate the role of CD47 and PD-L1 in this process, we engineered MYC T-ALL 4188 cells to constitutively express CD47 or PD-L1 ( fig. S12A ). In this overexpression system, CD47 and PD-L1 mRNA levels were unaffected by MYC inactivation (fig. S12B ). The recruitment of luciferase-labeled CD4 + T cells (Fig. 3A) , CD69 + -activated T cells, and F4/80 + macrophages (Fig. 3B and fig. S13 ) after MYC inactivation was suppressed when CD47 and PD-L1 were constitutively expressed by the tumor cells. Expression of CD47 or PD-L1 prevented the sustained tumor regression that has been observed upon MYC inactivation (Fig. 4A) , without affecting MYC expression (Fig. 4B) . Enforced expression of CD47 or PD-L1 increased minimal residual disease (tumor cells remaining), resulting in tumor recurrence (Fig. 4, C and D) . Conversely, shRNA knockdown of CD47 or PD-L1 prevented the growth of MYC T-ALL cells in vivo ( fig. S14) .
Inactivation of MYC induces tumor regression through both cell-autonomous mechanisms, including proliferative arrest and induction of apoptosis, and host-dependent mechanisms, such as inhibition of tumor angiogenesis and induction of tumor cell senescence (1-4, 13) . We investigated the effect of enforced expression of CD47 or PD-L1 on these mechanisms and found that CD47 or PD-L1 expression prevented the shutdown of angiogenesis after MYC inactivation, as measured by the presence of CD31 + microvessels (Fig. 4E and fig. S15A ) and expression of Ang2 and Tie2 (fig. S15C ). The induction of tumor cell senescence, as measured by b-galactosidase (Fig.  4F and fig. S15B ) and p15Ink4b and p19ARF levels ( fig. S15D) , was also affected, but we did not observe any effect on apoptosis or proliferation, as evaluated by annexin V and 7-AAD ( fig.  S16A), cleaved caspase 3 (fig. S16, B and D) , and phospho-histone H3 (fig. S16, C and E) . Therefore, the down-regulation of CD47 and PD-L1 appears to be required for the induction of sustained tumor regression, the shutdown of angiogenesis, and senescence induction promoted by MYC inactivation.
We conclude that MYC regulation of CD47 and PD-L1 expression has a direct role in the initiation . Data represent mean ± SEM derived from measurements of three independent tumors and three measurements per tumor. *P < 0.05; **P < 0.01; ***P < 0.001.
and maintenance of MYC-driven tumorigenesis (Fig. 4) . The overexpression of MYC may be one general mechanism by which tumor cells upregulate the expression of immune checkpoint regulators, thereby evading immune surveillance. MYC inactivation has been proposed to restore the immune response against tumors ( fig. S17 ) (39) (40) (41) . The suppression of MYC rapidly resulted in decreased mRNA and protein expression of CD47 and PD-L1, which suggests a transcriptional regulatory mechanism. MYC is a general transcriptional amplifier that can regulate gene expression through a multitude of mechanisms (32) (33) (34) . However, as noted above, MYC also exhibits transcriptional effects dependent on gene dosage (36, 42) . The relatively high levels of MYC expression that are associated with rapid proliferation and tumorigenesis may induce CD47 and PD-L1 expression.
Because MYC regulates transcription of their genes, CD47 and PD-L1 may be expressed at higher levels in the steady state as compared with other membrane proteins in tumors. Notably, MYC activation of the CD47 and PD-L1 genes appears to require higher levels of MYC binding to the CD47 and PD-L1 promoters compared with genes involved in normal cell growth; they may, therefore, represent promoters that have been invaded by oncogenic MYC levels (33, 42) . Thus, these genes may be particularly sensitive to MYC withdrawal.
Through the suppression of immune surveillance against tumor cells, MYC activation may influence cancer immunoediting. We propose that during tumor evolution, high levels of MYC expression result in increased expression of CD47 and PD-L1, suppressing both the innate and adaptive immune responses and favoring tumor growth ( fig. S17 ). Upon MYC inactivation, loss of the "don't find me" and "don't eat me" signals allows for the destruction of residual tumor cells and, consequently, sustained tumor regression.
Although the effects of MYC on the expression of CD47 and PD-L1 were modest, the consequences on tumor regression were dramatic, consistent with reports that small influences on immune regulators can have marked effects (25) . Both CD47 and PD-L1 may also contribute to the tumor microenvironment via their influence on T cell activation and angiogenesis (13, 14, 22, (43) (44) (45) . CD47 is the receptor for thrombospondin-1, which may regulate cellular programs including angiogenesis, self-renewal, and senescence (13, 14, 45 A decline in electron transport chain (ETC) activity is associated with many human diseases. Although diminished mitochondrial adenosine triphosphate production is recognized as a source of pathology, the contribution of the associated reduction in the ratio of the amount of oxidized nicotinamide adenine dinucleotide (NAD + ) to that of its reduced form (NADH) is less clear. We used a water-forming NADH oxidase from Lactobacillus brevis (LbNOX) as a genetic tool for inducing a compartment-specific increase of the NAD + /NADH ratio in human cells. We used LbNOX to demonstrate the dependence of key metabolic fluxes, gluconeogenesis, and signaling on the cytosolic or mitochondrial NAD + /NADH ratios. Expression of LbNOX in the cytosol or mitochondria ameliorated proliferative and metabolic defects caused by an impaired ETC. The results underscore the role of reductive stress in mitochondrial pathogenesis and demonstrate the utility of targeted LbNOX for direct, compartment-specific manipulation of redox state.
A decline in electron transport chain (ETC) activity has been linked to numerous human disorders, ranging from rare genetic syndromes to common diseases, such as neurodegeneration, cancer, and diabetes, as well as the aging process itself (1, 2) . How a decline in ETC activity gives rise to the spectrum of observed pathology cannot be readily explained by a simple deficiency in adenosine triphosphate (ATP) production (1) . A key challenge in deciphering mitochondrial pathogenesis stems from the fact that the ETC performs at
